Oct 032022
 
Drug Name
Active Ingredient(s)
Approval Date
FDA-Approved Use on Approval Date
Press Release
Drug Trials Snapshot
Lytgobi futibatinib 9/30/2022 To treat intrahepatic cholangiocarcinoma harboring fibroblast growth factor receptor 2 (FGFR2) gene fusions or other rearrangements Drug Trials Snapshot
Relyvrio sodium phenylbutyrate/taurursodiol 9/29/2022 To treat amyotrophic lateral sclerosis (ALS) Press Release Drug Trials Snapshot
Omlonti oomidenepag isopropyl ophthalmic solution 9/22/2022 To reduce elevated intraocular pressure in patients with open‑angle glaucoma or ocular hypertension Drug Trials Snapshot
Elucirem gadopiclenol 9/21/2022 To detect and visualize lesions, together with MRI, with abnormal vascularity in the central nervous system and the body Drug Trials Snapshot
Terlivaz terlipressin 9/14/2022 To improve kidney function in adults with hepatorenal syndrome with rapid reduction in kidney function Drug Trials Snapshot
Rolvedon eflapegrastim 9/9/2022 To decrease the incidence of infection in patients with non-myeloid malignancies receiving myelosuppressive anti-cancer drugs associated with clinically significant incidence of febrile neutropenia Drug Trials Snapshot
Sotyktu deucravacitinib 9/9/2022 To treat moderate-to-severe plaque psoriasis Drug Trials Snapshot
Daxxify daxibotulinumtoixnA-lanm 9/7/2022 To treat moderate-to-severe glabellar lines associated with corrugator and/or procerus muscle activity Drug Trials Snapshot
Spevigo spesolimab-sbzo 9/1/2022 To treat generalized pustular psoriasis flares Drug Trials Snapshot

Sorry, the comment form is closed at this time.